Montag & Caldwell LLC Cuts Holdings in Becton Dickinson and Co (BDX)

Montag & Caldwell LLC lowered its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 7.1% in the fourth quarter, Holdings Channel reports. The fund owned 455,427 shares of the medical instruments supplier’s stock after selling 34,984 shares during the quarter. Becton Dickinson and comprises about 3.1% of Montag & Caldwell LLC’s investment portfolio, making the stock its 17th biggest holding. Montag & Caldwell LLC’s holdings in Becton Dickinson and were worth $97,488,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in BDX. Hendley & Co. Inc. grew its holdings in Becton Dickinson and by 4.6% in the fourth quarter. Hendley & Co. Inc. now owns 7,736 shares of the medical instruments supplier’s stock valued at $1,656,000 after purchasing an additional 340 shares during the period. Armor Investment Advisors LLC grew its holdings in Becton Dickinson and by 4.4% in the fourth quarter. Armor Investment Advisors LLC now owns 9,083 shares of the medical instruments supplier’s stock valued at $1,944,000 after purchasing an additional 381 shares during the period. Autus Asset Management LLC grew its holdings in Becton Dickinson and by 22.1% in the fourth quarter. Autus Asset Management LLC now owns 7,399 shares of the medical instruments supplier’s stock valued at $1,583,000 after purchasing an additional 1,337 shares during the period. Victory Capital Management Inc. grew its holdings in Becton Dickinson and by 11.9% in the fourth quarter. Victory Capital Management Inc. now owns 4,708 shares of the medical instruments supplier’s stock valued at $1,008,000 after purchasing an additional 502 shares during the period. Finally, TCI Wealth Advisors Inc. grew its holdings in Becton Dickinson and by 36.8% in the fourth quarter. TCI Wealth Advisors Inc. now owns 1,238 shares of the medical instruments supplier’s stock valued at $265,000 after purchasing an additional 333 shares during the period. Institutional investors own 75.68% of the company’s stock.

Becton Dickinson and Co (BDX) opened at $237.11 on Monday. Becton Dickinson and Co has a 12-month low of $175.66 and a 12-month high of $248.39. The company has a debt-to-equity ratio of 1.44, a quick ratio of 5.03 and a current ratio of 5.58. The company has a market cap of $63,169.73, a price-to-earnings ratio of 50.99, a PEG ratio of 1.69 and a beta of 1.12.

The company also recently announced a quarterly dividend, which will be paid on Friday, March 30th. Stockholders of record on Friday, March 9th will be given a dividend of $0.75 per share. The ex-dividend date of this dividend is Thursday, March 8th. This represents a $3.00 dividend on an annualized basis and a dividend yield of 1.27%. Becton Dickinson and’s payout ratio is currently 64.52%.

BDX has been the subject of a number of recent analyst reports. Wells Fargo & Co restated a “positive” rating and issued a $235.00 target price (up from $225.00) on shares of Becton Dickinson and in a report on Tuesday, October 24th. They noted that the move was a valuation call. Argus boosted their price objective on shares of Becton Dickinson and to $235.00 and gave the stock a “buy” rating in a research note on Thursday, December 14th. They noted that the move was a valuation call. KeyCorp assumed coverage on shares of Becton Dickinson and in a research note on Friday, January 5th. They set an “overweight” rating and a $260.00 price objective for the company. Bank of America reiterated a “buy” rating and set a $260.00 price objective on shares of Becton Dickinson and in a research note on Friday, January 19th. Finally, Morgan Stanley boosted their price objective on shares of Becton Dickinson and from $205.00 to $245.00 and gave the stock an “equal weight” rating in a research note on Friday, November 3rd. Four research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $233.80.

WARNING: “Montag & Caldwell LLC Cuts Holdings in Becton Dickinson and Co (BDX)” was originally posted by Stock Observer and is owned by of Stock Observer. If you are accessing this piece on another publication, it was stolen and republished in violation of United States & international trademark and copyright laws. The correct version of this piece can be read at https://www.thestockobserver.com/2018/02/05/montag-caldwell-llc-cuts-holdings-in-becton-dickinson-and-co-bdx.html.

Becton Dickinson and Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply